Saturday, April 18, 2026
Search

Corporate Restructuring

4 articles

Private Credit Funds Lock Withdrawals as Asset Sales Hit Discounts, Raising Valuation Concerns

Private Credit Funds Lock Withdrawals as Asset Sales Hit Discounts, Raising Valuation Concerns

Blue Owl halted quarterly withdrawals from its retail fund while New Mountain Finance shares plunged to 2020 lows after discounted asset sales. The convergence of withdrawal restrictions, dividend cuts at FS KKR Capital, and defensive analyst positioning suggests private credit portfolios may face hidden credit deterioration masked by mark-to-model valuations.

ViaNews Editorial Team (Finance)
Corporate Debt Refinancing Surges as Eutelsat Secures €1.5B Credit Line, Buybacks Hit Record Pace

Corporate Debt Refinancing Surges as Eutelsat Secures €1.5B Credit Line, Buybacks Hit Record Pace

Eutelsat Communications closed a €1.5 billion debt refinancing in Q4 2025, part of a broader corporate restructuring wave spanning multiple sectors. Graco increased operating cash flow 10% to $684 million while funding aggressive buybacks. Companies are optimizing capital structures through refinancing, M&A deals including B&G Foods' College Inn acquisition and Tencent's Prenetics stake purchase, and shareholder returns via buyback programs at firms like Valero.

ViaNews Editorial Team (Finance)
Shaw Family Loses Corus Entertainment Equity in $1.2B Debt-for-Equity Swap

Shaw Family Loses Corus Entertainment Equity in $1.2B Debt-for-Equity Swap

The Shaw family faces complete equity wipeout in Corus Entertainment as the Canadian broadcaster executes a debt-for-equity swap with lenders. The restructuring transfers ownership from the billionaire family to creditors, ending decades of Shaw control over the media conglomerate that operates Global Television and specialty channels.

ViaNews Editorial Team (Finance)
Vectus Biosystems faces delisting risk as XORTX asset sale may leave insufficient capital

Vectus Biosystems faces delisting risk as XORTX asset sale may leave insufficient capital

Australian biotech Vectus Biosystems Limited confronts potential shareholder value erosion and ASX delisting if proceeds from its Renal Anti-Fibrotic Therapeutic Program sale to XORTX fail to cover ongoing operations. The medium-likelihood catastrophic risk stems from uncertainty over transaction value versus operational cash burn.

ViaNews Editorial Team (Finance)